Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ELVNNASDAQ:MTSRNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$63.92-2.0%$62.31$47.86▼$107.37$3.52B0.34599,907 shs1.08 million shsELVNEnliven Therapeutics$16.40-2.2%$18.46$13.30▼$30.03$822.89M1.07259,466 shs222,508 shsMTSRMetsera$27.30-2.7%$23.03$12.30▼$32.81$2.87BN/A894,216 shs1.10 million shsVKTXViking Therapeutics$26.98-2.7%$25.92$18.92▼$81.73$3.03B0.754.07 million shs1.80 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-1.98%+8.74%+0.46%+0.27%+17.80%ELVNEnliven Therapeutics-2.21%-2.73%-7.71%-24.77%-28.35%MTSRMetsera-2.67%-7.52%+15.78%-13.74%+2,729,999,900.00%VKTXViking Therapeutics-2.70%-5.10%+4.41%-20.81%-57.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.7853 of 5 stars3.50.00.00.03.32.50.0ELVNEnliven Therapeutics2.4848 of 5 stars3.62.00.00.01.94.20.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.4054 of 5 stars4.51.00.04.73.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3374.18% UpsideELVNEnliven Therapeutics 3.20Buy$37.25127.13% UpsideMTSRMetsera 3.00Buy$47.0072.16% UpsideVKTXViking Therapeutics 3.00Buy$87.15223.03% UpsideCurrent Analyst Ratings BreakdownLatest ELVN, ACLX, MTSR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M45.86N/AN/A$9.97 per share6.41ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AMTSRMetseraN/AN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%N/AELVNEnliven Therapeutics-$71.58M-$1.92N/AN/AN/AN/A-29.46%-27.33%8/12/2025 (Estimated)MTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest ELVN, ACLX, MTSR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29ELVNEnliven TherapeuticsN/A17.4417.44MTSRMetseraN/AN/AN/AVKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ELVNEnliven Therapeutics95.08%MTSRMetseraN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%ELVNEnliven Therapeutics29.20%MTSRMetseraN/AVKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.70 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableMTSRMetsera81105.06 millionN/AN/AVKTXViking Therapeutics20112.31 million106.20 millionOptionableELVN, ACLX, MTSR, and VKTX HeadlinesRecent News About These CompaniesBank of America Corp DE Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 24 at 3:29 AM | marketbeat.comViking Therapeutics: Weight-Loss Story Remains IntactMay 22 at 8:00 AM | seekingalpha.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Reduces Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 22 at 7:39 AM | marketbeat.comViking Therapeutics: A High Potential Biotech Play With Manageable RisksMay 20, 2025 | seekingalpha.comViking Therapeutics: Near-Term Catalysts And Competitor ReadoutsMay 20, 2025 | seekingalpha.comTang Capital Management LLC Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comTema Etfs LLC Invests $813,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $477,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comBNP Paribas Financial Markets Has $1.88 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 20, 2025 | marketbeat.comSecond Line Capital LLC Purchases 11,393 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 19, 2025 | marketbeat.comRafferty Asset Management LLC Has $10.91 Million Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 19, 2025 | marketbeat.comMan Group plc Boosts Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 19, 2025 | marketbeat.comSphera Funds Management LTD. Has $4.16 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 18, 2025 | marketbeat.comWhy Viking Therapeutics Stock Bumped 3% Higher TodayMay 16, 2025 | fool.comNorthern Trust Corp Increases Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 15, 2025 | marketbeat.comDimensional Fund Advisors LP Has $4.06 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 15, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)May 14, 2025 | theglobeandmail.comIntegral Health Asset Management LLC Sells 100,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 14, 2025 | marketbeat.com2 Monster Stocks in the Making to Buy Now and Hold for 10 YearsMay 13, 2025 | msn.comAmeriprise Financial Inc. Has $59.54 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Viking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportELVN, ACLX, MTSR, and VKTX Company DescriptionsArcellx NASDAQ:ACLX$63.92 -1.29 (-1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$63.82 -0.11 (-0.16%) As of 05/23/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Enliven Therapeutics NASDAQ:ELVN$16.40 -0.37 (-2.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$16.38 -0.02 (-0.12%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Metsera NASDAQ:MTSR$27.30 -0.75 (-2.67%) As of 05/23/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Viking Therapeutics NASDAQ:VKTX$26.98 -0.75 (-2.70%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$27.04 +0.06 (+0.24%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
